Clinical trial
A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT01536054 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Lead sponsor
- Roswell Park Cancer Institute
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 20, 2012
- Completion date
- April 21, 2015
- Enrollment
- 7 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent fallopian tube cancer, recurrent ovarian epithelial cancer, recurrent primary peritoneal cavity cancer, stage iia fallopian tube cancer, stage iia ovarian epithelial cancer, stage iia primary peritoneal cavity cancer, stage iib fallopian tube cancer, stage iib ovarian epithelial cancer, stage iib primary peritoneal cavity cancer, stage iic fallopian tube cancer, stage iic ovarian epithelial cancer, stage iic primary peritoneal cavity cancer, stage iiia fallopian tube cancer, stage iiia ovarian epithelial cancer, stage iiia primary peritoneal cavity cancer, stage iiib fallopian tube cancer, stage iiib ovarian epithelial cancer, stage iiib primary peritoneal cavity cancer, stage iiic fallopian tube cancer, stage iiic ovarian epithelial cancer, stage iiic primary peritoneal cavity cancer, stage iv fallopian tube cancer, stage iv ovarian epithelial cancer, stage iv primary peritoneal cavity cancer